New England Journal of Medicine

Patients on the trial reported better patient mobility and lung function after 12 months

Terlivaz is the first and only FDA-approved treatment for adults with HRS involving rapid reduction in kidney function

Results were presented at European Society of Cardiology Congress 2022, and published in 'New England Journal of Medicine'

The results from the trial, which was led by TB Alliance, were published in the 'New England Journal of Medicine'

Besides their tumours disappearing completely, none of the participants reported any severe side-effects either, says the research…

The findings, published in the 'New England Journal of Medicine,' has shown that cells called macrophages are primarily…

The recommendation is based on pivotal data from the phase-III Polarix study

The submission for the regulatory evaluation of the vaccine includes data from two phase-III clinical trials

Pfizer made the proposal in a 52-page presentation to the US FDA, which included data from the recent Israeli study, which showed…

The researchers speculate that the greater degree of clot formation and blood vessel generation in COVID-19 patients may have…